高级搜索
Survivin蛋白与非小细胞肺癌危险因素的系统评价[J]. 肿瘤防治研究, 2012, 39(09): 1087-1097. DOI: 10.3971/j.issn.1000-8578.2012.09.011
引用本文: Survivin蛋白与非小细胞肺癌危险因素的系统评价[J]. 肿瘤防治研究, 2012, 39(09): 1087-1097. DOI: 10.3971/j.issn.1000-8578.2012.09.011
Survivin Protein and Risk Factors in Non-small Cell Lung Cancer:A Systematic Review[J]. Cancer Research on Prevention and Treatment, 2012, 39(09): 1087-1097. DOI: 10.3971/j.issn.1000-8578.2012.09.011
Citation: Survivin Protein and Risk Factors in Non-small Cell Lung Cancer:A Systematic Review[J]. Cancer Research on Prevention and Treatment, 2012, 39(09): 1087-1097. DOI: 10.3971/j.issn.1000-8578.2012.09.011

Survivin蛋白与非小细胞肺癌危险因素的系统评价

Survivin Protein and Risk Factors in Non-small Cell Lung Cancer:A Systematic Review

  • 摘要: 目的 系统评价存活蛋白(Survivin)表达水平与非小细胞肺癌(non-small cell lung cancer,NSCLC)危险因素的关系。方法计算机检索Cochrane Library(2011年第1期),PubMed、CNKI等数据库,并辅以手工检索,按照纳入与排除标准选择病例对照试验。评价质量及提取资料后,采用RevMan 4.2.10软件对数据库进行系统评价。结果共纳入31个研究,其中2749例NSCLC患者,778例正常对照。Meta分析结果显示:Survivin在NSCLC组及正常对照组[比值比(odds ratio,OR)=11.11,95%可信区间(confidence interval,CI)=5.92~20.83] 的表达差异具有统计学意义(P<0.05)。临床病理结果显示:Survivin在T分期T3~T4期与T1~T2期(OR=2.20,95%CI:1.65~2.93)、临床分期Ⅲ~Ⅳ期与Ⅰ~Ⅱ期(OR=2.79,95%CI:1.23~6.35)、淋巴结转移组与非淋巴结转移组(OR=2.14,95%CI:1.36~3.35)、低分化组与中高分化组(OR=1.98,95%CI:1.27~3.08)间的表达差异均具有统计学意义(P<0.05)。Survivin在NSCLC男性组与女性组(OR=1.10,95%CI:0.87~1.40)、年龄<60岁组与≥60岁组(OR=1.05,95%CI:0.66~1.68)、吸烟组与非吸烟组(OR=1.18,95%CI:0.81~1.73)、病理类型鳞癌组与腺癌组(OR=1.24,95%CI:0.90~1.73)间的表达差异无统计学意义。进一步生存分析显示,Survivin阳性表达的患者5年生存率为26.69%,而阴性表达者为62.20%(OR=0.16,95%CI:0.04~0.66,P<0.05)。Spearman等级相关分析显示,Survivin与P53、Bcl-2蛋白阳性率在NSCLC中表达具有相关性(r=0.400,P<0.005;r=0.486,P<0.005)。结论Survivin在NSCLC中高表达,增加了其恶性行为的发生危险、降低了NSCLC患者5年生存率,同时Survivin与p53、Bcl-2在NSCLC表达也有一定的相关性。

     

    Abstract: Objective To investigate survivin protein and risk factors in non-small cell lung cancer(NSCLC) through a systematic review. Methods The published studies were searched from the Cochrane Library(Issue 1,2011),Pubmed and CNKI databases,and other relevant journals were also handsearched to identify all the relevant case-control trials.Then the quality of the included trials was assessed and meta-analysis was performed by RevMan 4.2.10 software. Results A total of 31 studies were recruited.As for the positive rate of survivin expression,significant differences were discovered between NSCLC and normal lung tissues(OR=11.11,95%CI:5.92~20.83,P<0.05).No significant difference was shown among gender(OR=1.10,95%CI:0.87~1.40 P>0.05),age(OR=1.05,95%CI:0.66~1.68,P> 0.05),smoking history(OR=1.18,95%CI:0.81~1.73,P>0.05),and histologic subtype(OR=1.24,95%CI:0.90~1.73,P> 0.05),respectively.There were significant differences between T3~4 and T1~2(OR=2.20,95% CI:1.65~2.93,P<0.05),clinic stages Ⅲ~Ⅳ and clinic stages Ⅰ~Ⅱ(OR=2.79,95%CI:1.23~6.35,P<0.05),lymph node metastasis and non-lymph node metastasis(OR=2.14,95%CI:1.36~3.35,P<0.05),cell differentiation G3 and cell differentiation G1~G2(OR=1.98,95%CI=1.27~3.08,P<0.05).Moreover,the overall survival time was significantly shorter in patients with survivin expression(26.69%) than that in patients with absent survivin expression (62.20%)(OR=0.16,95%CI=0.04~0.66,P<0.05).Survivin expression was positively correlated with p53 (r=0.400,P<0.005)and Bcl-2(r=0.486,P<0.005). Conclusion Survivin expression increased malignant behaviors of NSCLC,and meanwhile substantial correlation is confirmed between survivin and both p53 and Bcl-2.

     

/

返回文章
返回